<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957407</url>
  </required_header>
  <id_info>
    <org_study_id>71804161</org_study_id>
    <nct_id>NCT04957407</nct_id>
  </id_info>
  <brief_title>The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning</brief_title>
  <official_title>The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the gastric cancer database established earlier, this project explored the PG&#xD;
      standard suitable for Chinese people, and further explored the establishment of machine&#xD;
      learning model to stratify gastric cancer risk in the population, guide the frequency of&#xD;
      gastroscopy screening, and extract important gastric cancer risk factors from it.Establish&#xD;
      electronic health records of gastric organs, track the development and outcome of gastric&#xD;
      diseases through deep learning method, in order to predict the development and outcome of&#xD;
      gastric diseases;Then, the simulation hypothesis deductive method is used to compare the&#xD;
      outcomes that may be caused by different lifestyles with the help of deep learning model, so&#xD;
      as to guide patients to develop a better lifestyle and explore the establishment of health&#xD;
      management paths for gastric cancer patients and high-risk groups in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pepsinogen value for precanceous lesion and Gastric cancer</measure>
    <time_frame>1 year</time_frame>
    <description>pepsinogen value for precanceous lesion and Gastric cancer</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Precancerous Lesion</condition>
  <condition>Mechine Learning</condition>
  <arm_group>
    <arm_group_label>non-atrophic gastritis</arm_group_label>
    <description>OLGA-0 group；OLGA (Operative Link on Gastritis Assessment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mild-moderate atrophic gastritis</arm_group_label>
    <description>OLGA I-II group；OLGA (Operative Link on Gastritis Assessment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>severe atrophic gastritis</arm_group_label>
    <description>OLGA III-IV group；OLGA (Operative Link on Gastritis Assessment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gastric cancer</arm_group_label>
    <description>gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pepsinogen</intervention_name>
    <description>diagnostic value of pepsinogen for severe atrophy and gastric cancer</description>
    <arm_group_label>gastric cancer</arm_group_label>
    <arm_group_label>severe atrophic gastritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive subjects who underwent regular health checkup at nine International Healthcare&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1） intention to undergo gastroscopy during health checkup examination; and 2) 25-75&#xD;
             years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) a history of gastric ulcer, gastric polyp, or GC; 2) a history of gastrectomy; 3)&#xD;
             treatment with a proton pump inhibitor in the last month; 4) contraindications to&#xD;
             gastroscopy; 5) a history of Hp eradication; 6) a history of abdominal pain, abdominal&#xD;
             distention, belching, acid reflux, nausea and other digestive tract symptoms within 1&#xD;
             month or 67) incomplete data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuling Tong, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd affiliated hospital of Zhejiang University, school of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuling Tong, Dr.</last_name>
    <phone>1375821220</phone>
    <email>tongyl0313@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Zhao, Master</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Provincial Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuan Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo cadres health center</name>
      <address>
        <city>Ningbo</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tong Huang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

